title: Progestin facilitation of lordosis in rodents involves adenylyl cyclase activity in the ventral tegmental area.
abstract: Increasing cAMP, or activating dopamine type 1 (D(1)) or GABA(A)/benzodiazepine receptor complexes (GBRs), in the ventral tegmental area (VTA) enhances lordosis of rodents. Whether D(1)- and/or GBR-mediated increases in progestin-facilitated lordosis involve the cAMP-synthesizing enzyme, adenylyl cyclase, in the VTA, was investigated. In Experiment 1, ovariectomized estradiol (E(2); 10 microg at h 0)+progesterone (P; 250 microg at h 45)-primed hamsters first received bilateral infusions of the adenylyl cyclase inhibitor, 2',5'-dideoxyadenosine (DDA; 12 microM/side), or vehicle, and then were infused with the D(1) agonist, SKF38393 (100 ng/side), the GBR agonist, muscimol (100 ng/side), or vehicle, to the VTA. Lordosis was evaluated before and 30 min after each infusion. In Experiment 2, ovariectomized, E(2)-primed (10 microg at h 0) rats received VTA infusions of DDA (12 microM/side) or vehicle; SKF38393 (100 ng/side), muscimol (100 ng/side), or vehicle; and the neurosteroid, 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP; 100 or 200 ng/side), or beta-cyclodextrin vehicle. Lordosis was assessed before the series of infusions, immediately after drug infusions and 10 or 60 min after 3alpha,5alpha-THP infusions. Progestin- or progestin plus SKF38393-or muscimol-mediated increases in lordosis were blocked by DDA pretreatment. Thus, in the VTA, progestins' membrane action may involve adenylyl cyclase.
authors.affiliation: Department of Psychology, The University at Albany-SUNY, 1400 Washington Avenue, Albany, NY 12222, USA. cafrye@albany.edu
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Frye
authors.forename: Alicia A
authors.initials: AA
authors.lastname: Walf
authors.forename: Sandra M
authors.initials: SM
authors.lastname: Petralia
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D006224:Cricetinae; D018491:Dopamine Agonists / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D005260:Female; D018755:GABA Agonists / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009118:Muscimol / Q000494:pharmacology; D011187:Posture; D011372:Progestins / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D017447:Receptors, Dopamine D1 / Q000187:drug effects; D018079:Receptors, GABA / Q000187:drug effects; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D013268:Stimulation, Chemical; D017557:Ventral Tegmental Area / Q000201:enzymology*
chemical_list: D018491:Dopamine Agonists; D018755:GABA Agonists; D011372:Progestins; D017447:Receptors, Dopamine D1; D018079:Receptors, GABA; D009118:Muscimol; D004958:Estradiol; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D000262:Adenylyl Cyclases